tVNS and Depression: What the Evidence Actually Shows | For Clinicians | Neuromodulation for Rehabilitation

Why This Article?

Major depressive disorder (MDD) is among the most prevalent and disabling conditions worldwide. In the UK, roughly 1 in 6 adults experiences depression at any given time, and the condition accounts for a substantial proportion of NHS mental health expenditure, which exceeded £16 billion in 2023/24.

The clinical problem is compounded by treatment resistance. Approximately 30% of patients with MDD do not achieve adequate symptom control with standard pharmacotherapy, a condition termed treatment-resistant depression (TRD), typically defined as failure to respond to two or more adequate trials of antidepressant medication. UK-specific real-world data paints a particularly concerning picture: a European cross-sectional study found that UK TRD patients had been ill for longer, had more prior treatment failures, and had the worst treatment outcomes of all the countries studied (Heerlein et al., 2022).

After six months on a new antidepressant, only 16.7% of TRD patients achieve remission, rising to just 19.2% at twelve months. Beyond treatment resistance, many patients who do respond to antidepressants experience burdensome side effects: weight gain, sexual dysfunction, emotional blunting, and gastrointestinal disturbance. These factors contribute to poor adherence and treatment discontinuation.

This creates a genuine and well-documented unmet clinical need for effective, tolerable adjunctive or alternative treatments. As someone who has worked with electrical stimulation for many years, I have watched neuromodulation technologies evolve from curiosities into clinically validated tools. Vagus nerve stimulation is one of the most compelling examples. The surgically implanted version (VNS) received FDA approval for treatment-resistant depression in 2005. But not everyone is suitable for surgery, willing to undergo it, or able to access it.

This is where transcutaneous vagus nerve stimulation (tVNS) comes in: a non-invasive approach that delivers vagal stimulation through the skin of the ear, avoiding the need for surgery altogether. Anatomical Concepts distributes the tVNS® system in the UK, and this article provides clinicians with a thorough overview of the evidence for tVNS in depression. There are numerous wellness devices for vagus nerve stimulation, but only the tVNS® system is a regulated medical device and can substantiate medical claims.

What does the research actually show? Where is the evidence strong, and where are the gaps? What does this mean in practical clinical terms?

Let me walk you through it.

The Clinical Challenge: Treatment-Resistant Depression

Before looking at the solution, it's worth understanding the scale of the problem.

Treatment-resistant depression significantly impairs quality of life. It increases suicide risk, creates a substantial social, psychological, and economic burden for patients and their families, and drives disproportionate healthcare utilisation. The fact is that for many people living with TRD, the management challenge is not simply medical; it touches every aspect of daily life.

For eligible patients, electroconvulsive therapy (ECT) offers the highest acute response rates, but it requires general anaesthesia, repeated hospital visits, and carries cognitive side effects that many patients find unacceptable. Repetitive transcranial magnetic stimulation (rTMS) is effective but requires specialist clinic attendance for daily sessions over several weeks. Ketamine/esketamine offers rapid onset but raises concerns about durability, abuse potential, and cost.

Neuromodulation through the vagus nerve offers a fundamentally different approach: one that engages multiple neurobiological pathways simultaneously, can be self-administered at home, and builds in efficacy over time. The development of transcutaneous delivery systems removes the surgical barrier entirely, making vagal neuromodulation accessible earlier and to a broader population.

Why the Ear? The Anatomy Behind tVNS

If you're going to stimulate the vagus nerve through the skin, you need a reliable access point. The auricular branch of the vagus nerve (ABVN), sometimes called Arnold's nerve, provides exactly that.

The ABVN arises from the superior ganglion of the vagus nerve within the jugular foramen, traverses a small bony canal in the petrous bone, and emerges from the tympanomastoid fissure to innervate portions of the external ear. The cutaneous vagal afferent territory within the auricle includes the cymba conchae, concha, part of the tragus, and antihelix.

The critical issue is where on the ear you stimulate. The cadaver dissection study by Peuker and Filler (2002), the only published study examining vagal innervation density across auricular regions, established that the cymba conchae has 100% vagal innervation, compared with approximately 45% at the tragus. The cymba conchae is the only auricular region with purely vagal innervation and no overlapping innervation from other nerves.

The landmark fMRI study by Frangos et al. (2015) confirmed this in living humans. Cymba conchae stimulation produced significant activation of the nucleus tractus solitarius (NTS), locus coeruleus, dorsal raphe, amygdala, and nucleus accumbens. Earlobe stimulation (a region with minimal vagal innervation) did not produce these activations. This anatomical precision matters enormously: stimulation at the wrong site simply does not activate the brainstem pathways that drive the therapeutic effect.

In other words, not all ear-based VNS is equal. The site of stimulation is a critical variable.

How Does tVNS Work in Depression?

The antidepressant mechanism of tVNS is multifactorial, engaging overlapping neurobiological pathways that are directly relevant to depression pathophysiology. This mechanistic breadth is one of the most compelling aspects of the approach.

The Monoamine Pathways

Approximately 80% of vagal fibres are afferent, conveying sensory information from the periphery to the brainstem. The primary relay station is the nucleus tractus solitarius (NTS) in the medulla. From the NTS, signals project to two centres that are central to depression neurobiology:

The locus coeruleus (LC) is the brain's principal source of norepinephrine. The LC-norepinephrine system modulates attention, arousal, stress response, and emotional processing. Dysregulation of this system is a core feature of depression. tVNS-induced activation of the LC increases norepinephrine release, the same mechanism targeted by serotonin-norepinephrine reuptake inhibitors (SNRIs).

The raphe nuclei are the brain's major serotonin source. Serotonergic dysfunction is the most established neurochemical model of depression and the target of SSRIs. NTS projections to the raphe nuclei provide a direct pathway through which tVNS can modulate serotonin signalling.

A head-to-head trial comparing taVNS with citalopram (Li et al., 2022) demonstrated that both treatments produced significant increases in peripheral blood levels of serotonin, dopamine, GABA, and noradrenaline, with no significant difference between groups. This provides direct biochemical evidence that tVNS engages the same neurotransmitter systems targeted by conventional antidepressants.

HPA Axis Modulation

Depression is associated with chronic activation of the hypothalamic-pituitary-adrenal (HPA) axis, resulting in elevated cortisol and corticotropin-releasing hormone (CRH). Research on implanted VNS has demonstrated that CRH/ACTH responses that were significantly elevated before VNS treatment were reduced to normal values after treatment (O'Keane et al., 2005). Neuroimaging studies of tVNS specifically show deactivation of the hypothalamus during stimulation, directly relevant to resetting dysfunctional HPA axis circuits.

The Cholinergic Anti-Inflammatory Pathway

There is now substantial evidence linking neuroinflammation to depression. Patients with MDD consistently show elevated levels of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. Meta-analyses confirm these are significantly elevated in depression compared with healthy controls.

tVNS engages the "inflammatory reflex" via the cholinergic anti-inflammatory pathway. Vagal afferents trigger an efferent response that results in the release of acetylcholine in the spleen, which binds to alpha-7 nicotinic acetylcholine receptors on macrophages, inhibiting the release of pro-inflammatory cytokines. In a clinical trial of 35 patients, the taVNS group showed significant reductions in normalised aggregate pro-inflammatory cytokines and IL-6 levels compared with sham, and each 1 pg/mL reduction in IL-6 correlated with a 0.798-point improvement in clinical outcomes.

This is particularly relevant because the "inflammatory subtype" of depression (characterised by elevated CRP and inflammatory markers) may represent a distinct population that is especially amenable to anti-inflammatory interventions.

Neuroplasticity and BDNF

VNS drives expression of brain-derived neurotrophic factor (BDNF), a key regulator of neuroplasticity. BDNF levels are characteristically reduced in depression and increase with successful antidepressant treatment. VNS increases phosphorylation of the BDNF receptor TrkB, engaging downstream effectors including CREB that drive synaptic plasticity. This neuroplasticity-promoting effect may underpin the observation that VNS produces a slow but sustained antidepressant response that builds over weeks to months.

Network-Level Effects

Neuroimaging studies from tVNS-treated MDD patients demonstrate measurable changes in brain network architecture:

Decreased functional connectivity in the default mode network (DMN), which is characteristically overactive in depression
Increased amygdala to dorsolateral prefrontal cortex connectivity, associated with improved emotional regulation
Increased nucleus accumbens connectivity with medial prefrontal cortex and anterior cingulate cortex
Modulation of the salience network, which determines how the brain processes and prioritises emotional information

These changes are consistent with normalisation of the aberrant neural network patterns that characterise depression.

KEY POINT: The mechanisms of tVNS in depression are multi-layered. The monoamine pathways (norepinephrine via the locus coeruleus, serotonin via the raphe nuclei) are the best-established mechanisms, but HPA axis modulation, anti-inflammatory effects, neuroplasticity through BDNF, and network-level reorganisation all appear to contribute. This mechanistic breadth may explain why tVNS can match the neurotransmitter effects of an SSRI while also engaging pathways that pharmacotherapy does not directly target.

Stimulation Delivery: Devices and Parameters

The Devices

Two main transcutaneous routes are used in practice:

Transcutaneous auricular VNS (taVNS) applies electrodes to the external ear to target the ABVN. This is the most studied approach for depression. The most clinically validated platform is the tVNS® system (tVNS Technologies GmbH, Germany), CE-marked since 2010 and now holding Class IIa certification under EU-MDR 2017/745. It is the device distributed by Anatomical Concepts in the UK.

Transcutaneous cervical VNS (tcVNS) applies electrodes over the sternocleidomastoid to stimulate the cervical vagus trunk. The gammaCore® (electroCore) is FDA-cleared for migraine and cluster headache but not for depression.

Stimulation Parameters

Clinical trials in depression have used varying parameters, though a general consensus is emerging:

Parameter	Range Across Trials	Most-Used in Depression Trials
Frequency	1.5 to 120 Hz	20 to 25 Hz
Pulse width	200 to 500 µs	200 to 500 µs
Intensity	Sub-pain threshold	Maximum tolerated (typically 4 to 6 mA)
Duty cycle	Continuous or 30s on/off	Continuous (depression trials)
Daily duration	15 min to 4 h	30 min twice daily

The convention is to stimulate the left ear, following the practice established for implanted VNS (due to the asymmetric cardiac innervation of right vs. left vagus).

The most commonly used depression protocol, and the one with the strongest clinical data, is 20 Hz, 200 to 500 µs pulse width, 4 to 6 mA (titrated to sensory threshold), 30 minutes twice daily at the cymba conchae (the Rong/Kong protocol).

There is currently no consensus on optimal stimulation parameters for depression. This is one of the most significant barriers to clinical translation. The AddVNS study (protocol published 2026) represents the first well-designed, double-blind, sham-controlled trial specifically aiming to elucidate optimal parameters and biological mechanisms for tVNS in depression.

The Clinical Evidence: What Do the Trials Show?

This is the section that matters most for clinicians making decisions. Let me present the evidence systematically.

Hein et al. (2013): The First RCT

The first randomised controlled trial of taVNS for depression enrolled 37 patients with MDD in a sham-controlled study. Stimulation was applied at 1.5 Hz, 0.13 mA, for 15 minutes one to two times daily over two weeks. The active group showed a BDI reduction of 12.6 points versus 4.4 points in the sham group (p = 0.004). However, there was no significant difference on the clinician-rated HAMD between groups.

This dissociation between self-rated and clinician-rated outcomes was notable and has been a recurring theme in the field. The study was also limited by its small sample size, short duration, and unusually low stimulation parameters.

Rong/Kong et al. (2016): The Largest Pilot Study

This controlled study enrolled 160 MDD patients across two cohorts. The first cohort (n=91) received taVNS for 12 weeks. The second cohort (n=69) received four weeks of sham taVNS followed by eight weeks of real taVNS. Stimulation was applied at 20 Hz, 200 µs pulse width, 4 to 6 mA, 30 minutes twice daily at the cymba conchae. Patients self-administered at home.

The results at week 4 (taVNS vs sham):

HAMD-24 scores: 16.0 vs 20.6 (effect size 0.57, 95% CI 4.5 to 8.3, p < 0.0001)
Response rate (≥50% HAMD reduction): 27% vs 0% (p < 0.00001)

Longer-term results (taVNS group through 12 weeks):

Week 8 response rate: 53%
Week 12 response rate: 80%
Week 12 remission rate (HAMD < 8): 39%

taVNS also significantly reduced anxiety, sleep disturbance, psychomotor retardation, and hopelessness. Adverse events were limited to tinnitus (2 cases in active, 3 in sham), all resolving on cessation.

Two observations stand out. First, the response rate built substantially over time, from 27% at week 4 to 80% at week 12. This cumulative pattern is consistent with the known time course of VNS neuromodulation and has practical implications: patients and clinicians need to commit to at least 8 to 12 weeks before judging response. Second, the effect size of 0.57 at four weeks is clinically meaningful.

KEY POINT: The Rong/Kong study illustrates the importance of treatment duration. The response rate more than tripled between week 4 (27%) and week 12 (80%). This is consistent with the neuroplasticity-driven mechanism of VNS and has direct implications for clinical practice: early assessment at 4 weeks may underestimate the true treatment effect.

Li et al. (2022): taVNS vs Citalopram

A prospective, single-blind, comparative effectiveness trial randomised 107 patients with MDD to either taVNS (n=55; 8 weeks treatment, twice daily) or citalopram (n=52; 12 weeks, 40 mg/day).

HAM-D17 scores reduced in both groups with no significant group-by-time interaction (p = 0.79)
taVNS produced significantly higher remission rates at weeks 4 and 6 compared with citalopram
Both treatments produced significant increases in serotonin, dopamine, GABA, and noradrenaline
No significant difference between groups in neurotransmitter changes

The finding that taVNS produced symptom improvement comparable to a standard SSRI is clinically significant. However, the absence of a placebo/sham arm means placebo effects cannot be excluded from either group.

DELOS-1 (2022): Peripartum Depression

A multicentre, open-label, proof-of-concept trial enrolled 25 women with MDD with peripartum onset. At week 6, least squares mean change in HAM-D17 was -9.7, with a 74% response rate and 61% remission rate. 95% of clinicians and 96% of participants reported at least some improvement. This is a population where non-pharmacological options are particularly valued due to concerns about medication exposure during breastfeeding.

Liu et al. (2024): Post-Stroke Depression

A double-blind, randomised, placebo-controlled trial examined taVNS combined with conventional treatment for post-stroke depression. The combination significantly reduced HAMD scores, with evidence of amygdala to dorsolateral prefrontal cortex connectivity changes associated with depression improvement. This suggests taVNS may have particular relevance for depression secondary to neurological conditions.

iWAVE Pilot Trial (2025): Accelerated Inpatient taVNS

Ten adult psychiatric inpatients with comorbid depression and anxiety received accelerated taVNS. Stimulation significantly reduced PHQ-9 (mean reduction -6.00, p < 0.05), BDI (-11.00, p < 0.05), GAD-7 (-5.90, p < 0.05), and BAI (-9.40, p < 0.05). This was the first study to explore accelerated dosing protocols, raising the possibility of more intensive initial treatment.

What the Meta-Analyses Tell Us

The largest meta-analysis (Wang et al., 2023, 12 RCTs, 838 participants) found:

taVNS significantly improved depression scores and reduced HAMD scores
Higher response rates than sham taVNS
Comparable response rates to antidepressants
taVNS combined with antidepressants showed comparable efficacy to antidepressants alone but with fewer side effects

However, the evidence was rated as "low to very low" quality by GRADE standards. A systematic review by Li et al. (2024) identified only five human studies (306 patients) and concluded that while feasibility and positive signals exist, "it is still inconclusive whether taVNS is clinically effective to treat depression."

It is worth being straightforward about what these findings mean. The meta-analytic evidence supports a genuine antidepressant signal for tVNS, but the evidence base remains limited in quality and quantity. Larger, better-designed trials are needed before definitive conclusions can be drawn.

KEY POINT: The clinical evidence for tVNS in depression includes multiple controlled trials, a 160-patient pilot study, head-to-head comparison with citalopram, and two meta-analyses. The consistent finding is a statistically and clinically meaningful reduction in depression scores with a favourable safety profile. Response rates of 27 to 80% and remission rates of 39 to 61% have been reported, though these come predominantly from open-label or non-randomised designs. The evidence is encouraging but not yet definitive.

The Implanted VNS Context

Understanding the implanted VNS evidence base is important context for tVNS, because it establishes that vagal neuromodulation has genuine, sustained antidepressant effects.

The Aaronson et al. (2017) 5-year registry study at 61 US sites with 795 patients remains the most compelling evidence:

5-year cumulative response rate: VNS + treatment as usual: 67.6% vs treatment as usual alone: 40.9%
5-year cumulative remission rate: VNS: 43.3% vs TAU: 25.7%
Duration of remission: VNS: 40 months vs TAU: 19 months

Among ECT non-responders, VNS still achieved a 59.6% response rate. This demonstrates that vagal neuromodulation can succeed where other approaches have failed, and that the benefit builds and sustains over years.

The more recent RECOVER trial (2024, n=493, sham-controlled) did not meet its primary endpoint, though significant benefits were observed on multiple secondary endpoints including clinician-rated improvement, patient-reported outcomes, and quality of life. The failure of the primary endpoint may reflect the slow-building nature of VNS efficacy, which requires longer than typical trial durations to fully develop.

How Does tVNS Compare with Other Approaches?

This is a question clinicians rightly ask. The honest answer is that no head-to-head trials comparing tVNS with rTMS, ECT, or other neuromodulation exist for depression. With that caveat, here is what we can say:

Feature	ECT	rTMS	Implanted VNS	tVNS
Response rate	~64%	~49%	67.6% (5-year)	27 to 80% (varies by study)
Remission rate	~53%	~32%	43.3% (5-year)	39 to 61% (varies by study)
Surgery/anaesthesia	General anaesthesia	No	Surgical implant	No
Setting	Hospital	Specialist clinic	Specialist centre	Home-based
Session frequency	2 to 3x/week	Daily for 4 to 6 weeks	Continuous	Daily self-administered
Cognitive side effects	Common	Rare	None established	None reported
Cost	High	Moderate to high	Very high (£20,000 to 50,000+)	Low (hundreds to low thousands)
Reversibility	N/A	N/A	Requires surgery to remove	Fully reversible

Important caveat: These figures are not directly comparable due to different study populations, designs, outcome measures, and timeframes. The tVNS response/remission rates are predominantly from open-label studies and are likely inflated compared with what would be observed in rigorous sham-controlled RCTs.

tVNS occupies a distinctive position: it is the most accessible modality (home-based, no specialist equipment, no anaesthesia) and has the lowest barrier to entry. While its evidence base is less mature than ECT, rTMS, or implanted VNS, it offers a practical option for patients who cannot access or tolerate other approaches.

KEY POINT: tVNS is not a replacement for established treatments. It is an additional option, particularly suited to patients who have not responded adequately to pharmacotherapy, who cannot access or tolerate rTMS or ECT, or who are seeking a non-pharmacological approach that can be used at home. Its accessibility, reversibility, and substantially lower cost make it especially appealing in practice.

Safety Profile

One of the most compelling aspects of tVNS is its safety record. Across all published depression trials, no serious device-related adverse events have been reported.

Common, mild and transient (reported in up to 20 to 25% of patients):

Local skin effects: erythema, tingling, itching at electrode site
Headache
Dizziness

Uncommon:

Tinnitus (resolves on cessation)
Nausea
Nasopharyngitis

A systematic review and meta-analysis of 177 studies involving 6,322 subjects found no significant difference in the risk of adverse events between taVNS and control groups (Redgrave et al., 2018). After two-week tVNS interventions, no effects on heart rate, blood pressure, or blood test parameters were found.

By comparison, antidepressant medications commonly cause weight gain (up to 25% of patients), sexual dysfunction (up to 70%), emotional blunting, gastrointestinal disturbance, and discontinuation syndrome. ECT carries risks of cognitive impairment. Implanted VNS carries surgical risks including infection (3 to 7%), vocal cord paresis, and hoarseness affecting up to 40% of patients. The avoidance of these complications represents a major practical advantage.

Cardiac monitoring is prudent at initiation, particularly in patients with pre-existing cardiac disease. But in my experience with neuromodulation devices, the safety profile of tVNS is genuinely reassuring.

Regulatory and Access Context

The tVNS® E device (tVNS Technologies GmbH, Germany) received CE marking for epilepsy and depression in 2010 and now holds Class IIa certification under EU-MDR 2017/745, verified by TÜV SÜD. The EU-MDR approval covers depression as a specific, approved indication, making it the only non-invasive VNS device with this level of EU-MDR approval for depression.

Implanted VNS (LivaNova) received FDA approval for TRD in 2005 but remains non-covered by Medicare/Medicaid in the United States. The gammaCore® holds FDA clearance for headache indications but not for depression.

For UK practice, there is currently no NICE interventional procedure guidance or technology appraisal specifically for tVNS in depression. NICE guidance on rTMS for depression (IPG542) exists, but equivalent guidance for tVNS has not been issued. Given the CE marking under EU-MDR 2017/745, tVNS can be used in UK clinical practice for depression, though formal NICE guidance specific to tVNS for depression is currently lacking. This is a gap that deserves attention as the evidence base continues to grow.

Predicting Response: Who Benefits Most?

Response to tVNS is heterogeneous. Not everyone responds equally, and being honest about this matters. Several predictive factors have been identified:

Heart rate variability (HRV): A 2025 study in Translational Psychiatry found that patients with low baseline RMSSD (indicating low vagal tone, as commonly seen in depression) showed the greatest improvement in HRV measures with taVNS. This suggests patients with autonomic dysregulation may benefit most.
fMRI-based prediction: A 2024 study used resting-state fMRI and machine learning in 86 MDD patients to identify brain functional connections that predicted treatment response, demonstrating the feasibility of neuroimaging-guided patient selection.
Depression severity: The strongest clinical data is for mild to moderate depression. Evidence for severe or markedly treatment-resistant depression is limited for transcutaneous approaches, though implanted VNS shows benefit even in this population.
Inflammatory profile: Given the anti-inflammatory mechanism, there is a theoretical rationale for expecting greater benefit in patients with elevated inflammatory markers (CRP, IL-6), though this has not been formally tested in taVNS trials.

These predictive markers are not yet routinely applied in clinical practice, but they represent an important direction for personalising patient selection.

Beyond Depression: Comorbidity Benefits

Depression rarely exists in isolation, and tVNS has shown benefits across several common comorbidities:

Anxiety: The Rong/Kong study demonstrated significant reductions in anxiety alongside depression (HAMA effect size 0.3, p < 0.0001). The iWAVE trial showed significant reductions in GAD-7 and BAI scores. The tVNS device is EU-MDR approved for anxiety as well as depression.
Sleep: taVNS significantly improved sleep quality, with specific improvements in sleep disturbance subscores. The mechanism may involve modulation of the default mode network and hypothalamic deactivation during stimulation.
Cognitive function: fMRI evidence of increased frontal cortex activation and network reorganisation suggests a neurobiological basis for cognitive improvement. Working memory improvements have been reported following taVNS.
Inflammatory markers: Clinical evidence shows taVNS reduces IL-6 and aggregate pro-inflammatory cytokines, with reductions correlating with clinical improvement.

The dual antidepressant and anxiolytic profile of tVNS is clinically attractive for this population, where anxiety is the most common comorbidity.

What We Don't Yet Know

Here are the key unanswered questions:

Large sham-controlled RCTs: No large, rigorous, sham-controlled RCT exists specifically for taVNS in depression in Western populations. The AddVNS study (protocol published 2026) aims to address this gap.

Sham control design: The paresthesia produced by active stimulation can unblind participants. A Cochrane Risk of Bias assessment of 41 aVNS RCTs found only two with "low" risk of bias, with blinding identified as the primary concern.

Parameter optimisation: There is no consensus on optimal stimulation parameters for depression. Frequency, pulse width, intensity, duration, and schedule vary widely across studies.

Long-term outcomes: The longest controlled comparison for taVNS in depression is 12 weeks. Whether the sustained, building response seen with implanted VNS over years also occurs with taVNS is unknown but plausible given the shared mechanism.

Treatment-resistant populations: Most taVNS trials enrolled mild to moderate depression. Data in truly treatment-resistant populations is sparse for transcutaneous approaches.

Head-to-head comparisons: No trial has directly compared taVNS with rTMS, tDCS, or other non-invasive neuromodulation for depression.

Dose-response relationship: Whether more stimulation produces better outcomes is unclear.

Western population data: The majority of taVNS depression evidence comes from Chinese populations. Generalisability to UK/European populations requires confirmation.

Practical Guidance for Clinicians

For UK clinicians considering taVNS in depression management, the following practical points are relevant.

Candidate Selection

Adults with MDD who have not responded adequately to at least one adequate trial of antidepressant medication
Patients seeking non-pharmacological or adjunctive treatment options
Patients unable to access or tolerate rTMS or ECT
Peripartum depression where non-pharmacological approaches are preferred
Absence of cardiac pacemakers or implanted metallic devices near the ear
Exclusion of severe cardiac arrhythmia

Treatment Initiation

Consider maintaining stable medication regimen during initial assessment period
Titrate intensity to maximum tolerated (just below pain threshold), typically 4 to 6 mA
20 to 25 Hz, 200 to 500 µs pulse width, 30 minutes twice daily (can be divided into sessions)
Assess response at 4, 8, and 12 weeks using a standardised measure (PHQ-9 or HAMD)
Allow at least 8 to 12 weeks before judging response, as benefit builds over time

What to Tell Your Patients

The antidepressant benefit typically becomes apparent from 4 to 8 weeks, with continued improvement through 12 weeks and possibly beyond. This is not a quick fix.
Based on the available evidence, response rates of 50 to 80% have been reported at 8 to 12 weeks, though these figures come from studies that may overestimate the true effect.
Mild local side effects (tingling, redness at the electrode site) are expected and generally well tolerated.
The device is typically used as an adjunct to existing treatment, not necessarily a replacement for medication. Any medication changes should be discussed with the prescribing clinician.
Building sessions into a daily routine (while reading, watching television, or resting) helps with adherence.

Comorbidity Considerations

Anxiety is extremely common in depression. The dual antidepressant and anxiolytic profile of tVNS is clinically attractive for this population. Sleep improvements may also be observed. Cognitive and quality-of-life benefits may take longer than mood benefits to emerge.

Conclusion

The most honest summary is this: transcutaneous vagus nerve stimulation is a biologically plausible, mechanistically coherent, and clinically encouraging approach to the adjunctive management of depression. The neurophysiological rationale is well grounded in the monoamine, neuroendocrine, anti-inflammatory, and neuroplasticity pathways, supported by direct human biomarker and neuroimaging studies. The clinical evidence, including multiple controlled trials, a head-to-head comparison with citalopram, and two meta-analyses, demonstrates a significant and clinically meaningful reduction in depression scores with an excellent safety profile.

The evidence is not yet at the level of rTMS or ECT, which have larger and more rigorous trial databases. The quality of existing tVNS evidence is rated as low to very low by GRADE standards, largely due to small sample sizes, heterogeneous protocols, and methodological concerns about blinding. Large, well-designed, sham-controlled RCTs in Western populations with treatment-resistant depression are the critical gap.

What the evidence does support is that tVNS is safe, well-tolerated, biologically rational, and has a credible and growing body of clinical data. As a CE-marked Class IIa medical device with regulatory approval specifically for depression, it represents a legitimate clinical option. Its accessibility (home-based, self-administered), reversibility, substantially lower cost, and dual indication for comorbid anxiety make it especially appealing in practice.

The coming years, with trials such as AddVNS, should provide the higher-quality evidence needed to clarify the magnitude of effect, optimal parameters, and the patients most likely to benefit.

Related Literature

Peuker ET, Filler TJ. The nerve supply of the human auricle. Clin Anat. 2002;15(1):35-37.
O'Keane V, Dinan TG, Scott L, Corcoran C. Changes in hypothalamic-pituitary-adrenal axis measures after vagus nerve stimulation therapy in chronic depression. Biol Psychiatry. 2005;58(12):963-968.
Follesa P, Biggio F, Gorini G, et al. Vagus nerve stimulation and neurotrophins: a biological psychiatric perspective. Neurosci Biobehav Rev. 2007;31(5):748-773.
Hein E, Nowak M, Kiess O, et al. Auricular transcutaneous electrical nerve stimulation in depressed patients: a randomized controlled pilot study. J Neural Transm. 2013;120(3):403-408.
Frangos E, Ellrich J, Komisaruk BR. Non-invasive access to the vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans. Brain Stimul. 2015;8(3):624-636.
Trevizol AP, Shiozawa P, Taiar I, et al. Transcutaneous auricular vagus nerve stimulation in treating major depressive disorder: a systematic review and meta-analysis. Arq Neuropsiquiatr. 2015;73(11):964-970.
Rong P, Liu J, Wang L, et al. Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder: a nonrandomized controlled pilot study. J Affect Disord. 2016;195:172-179.
Aaronson ST, Sears P, Ruvuna F, et al. A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. Am J Psychiatry. 2017;174(7):640-648.
Yakunina N, Kim SS, Nam EC. Optimization of transcutaneous vagus nerve stimulation using functional MRI. Neuromodulation. 2017;20(3):290-300.
Redgrave J, Day D, Leung H, et al. Safety and tolerability of transcutaneous vagus nerve stimulation in humans: a systematic review. Brain Stimul. 2018;11(6):1225-1238.
Farmer AD, Strzelczyk A, Finisguerra A, et al. International consensus based review and recommendations for minimum reporting standards in research on transcutaneous vagus nerve stimulation (version 2020). Front Hum Neurosci. 2021;14:568051.
Li S, Rong P, Wang Y, et al. Comparative effectiveness of transcutaneous auricular vagus nerve stimulation vs citalopram for major depressive disorder: a randomized trial. Neuromodulation. 2022;25(3):450-460.
Farmer AD, et al. Safety of transcutaneous auricular vagus nerve stimulation: a systematic review and meta-analysis. Sci Rep. 2022;12(1):22077.
Gokce Coskun E, et al. Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder with peripartum onset (DELOS-1). J Affect Disord. 2022;317:273-282.
Heerlein K, Young AH, Otte C, et al. Real-world evidence from a European cohort study of patients with treatment-resistant depression: treatment patterns and clinical outcomes. BMC Psychiatry. 2022;22:617.
Wang Y, Li C, et al. The efficacy and safety of transcutaneous auricular vagus nerve stimulation in the treatment of depressive disorder: a systematic review and meta-analysis. J Affect Disord. 2023;337:37-49.
Li H, et al. Neural, anti-inflammatory, and clinical effects of transauricular vagus nerve stimulation in major depressive disorder: a systematic review. Int J Neuropsychopharmacol. 2024;27(3):pyad058.
Liu Y, et al. Transcutaneous auricular vagus nerve stimulation for post-stroke depression: a double-blind, randomized, placebo-controlled trial. J Affect Disord. 2024;354:82-88.
Conway CR, et al. Vagus nerve stimulation in treatment-resistant depression: the RECOVER trial. Brain Stimul. 2024;17(6):1236-1244.
Ashley EA, Cox S, Badran BW, et al. Accelerated transcutaneous auricular vagus nerve stimulation for inpatient depression and anxiety: the iWAVE pilot trial. Neuromodulation. 2025.
Baseline heart rate variability as guide to transcutaneous auricular vagus nerve stimulation in depression. Transl Psychiatry. 2025;15:Article 3780.
Protocol of the randomized double blind sham controlled AddVNS study of transcutaneous vagus nerve stimulation mechanisms in depression. Sci Rep. 2026;16:Article 42459.

Review current as of April 2026. Based on evidence available up to and including early 2026.